Quantitative visual pathway abnormalities predict visual field defects in patients with pituitary adenomas: a diffusion spectrum imaging study

Quantitative Parameters of Diffusion Spectrum Imaging: HER2 Status Prediction in Patients With Breast Cancer

“…DSI is a model freely reconstructed by using multiple bvalues and gradient directions in the entire q-space to sample diffusion signals of water molecules and to quantitatively estimate them by probability density function (8), which is mathematically and physically superior to other diffusion MRI techniques (9). Clinically, it has been used in the diseases of the central nervous system (10,11). In breast cancer, some diffusion models, including DWI, DTI, and DKI, have been applied to predict the HER2 status but showing a poor performance (12)(13)(14)(15), partly due to the limitation of specific model assumptions (9).…”

The application of functional imaging in visual field defects: a brief review

“…Liang et al examined the clinical utility of DSI for the quantitative assessment of visual pathway irregularities, with the aim of predicting the extent of VFDs in patients with pituitary adenoma. Their findings led to the conclusion that DSI can offer quantitative data to identify visual abnormalities and may serve as a potential diagnostic tool for assessing the degree of VFDs in pituitary adenoma cases ( 65 ).…”

Methods of diffusion MRI tractography for localization of the anterior optic pathway: A systematic review of validated methods

“…One study was excluded because it was conducted ex vivo on anatomical dissection ( Roebroeck et al, 2008 ). The remaining 39, published between 2007 and 2022, were included in the systematic review ( Akazawa et al, 2010 , Allen et al, 2018 , Altıntaş et al, 2017 , Ather et al, 2019 , Chakravarthi et al, 2021 , Davies-Thompson et al, 2013 , de Blank et al, 2013 , Ge et al, 2015 , Hajiabadi et al, 2015 , Hajiabadi et al, 2016 , He et al, 2021 , Ho et al, 2019 , Hodaie et al, 2010 , Hofer et al, 2010 , Jacquesson et al, 2019a , Jin et al, 2019 , Kamali et al, 2014 , Kammen et al, 2016 , Lacerda et al, 2021 , Lecler et al, 2018 , Liang et al, 2021 , Lin et al, 2018 , Lober et al, 2012 , Ma et al, 2016 , Maleki et al, 2012 , Manners et al, 2022 , Miller et al, 2019 , Puzniak et al, 2019 , Puzniak et al, 2021 , Salmela et al, 2009 , Staempfli et al, 2007 , Takemura et al, 2019 , Tao et al, 2009 , Techavipoo et al, 2009 , Wu et al, 2019 , Yang et al, 2011 , Yoshino et al, 2016 , Zhang et al, 2012b , Zolal et al, 2017 ) .

Fig.

…”

“…Eight (20.5%) studies were conducted only on healthy volunteers ( Akazawa et al, 2010 , He et al, 2021 , Hofer et al, 2010 , Jin et al, 2019 , Kamali et al, 2014 , Kammen et al, 2016 , Maleki et al, 2012 , Staempfli et al, 2007 ), seven (17.9%) in patients affected by genetic conditions (e.g., albinism, congenital achiasma, Leber’s hereditary optic neuropathy) ( Ather et al, 2019 , Davies-Thompson et al, 2013 , Lecler et al, 2018 , Manners et al, 2022 , Puzniak et al, 2019 , Puzniak et al, 2021 , Takemura et al, 2019 ), three (7.7%) in patients affected by ophthalmological pathologies (e.g., amblyopia, aniridia, glaucoma) ( Allen et al, 2018 , Altıntaş et al, 2017 , Miller et al, 2019 ), nineteen (48.7%) in patients with tumors or other expansive processes ( de Blank et al, 2013 , Ge et al, 2015 , Hajiabadi et al, 2015 , Hajiabadi et al, 2016 , Ho et al, 2019 , Hodaie et al, 2010 , Jacquesson et al, 2019a , Liang et al, 2021 , Lin et al, 2018 , Lober et al, 2012 , Ma et al, 2016 , Salmela et al, 2009 , Tao et al, 2009 , Wu et al, 2019 , Yoshino et al, 2016 , Zhang et al, 2012b , Zolal et al, 2017 ), one (2.6%) in patients affected by demyelinating disorders (e.g., multiple sclerosis, neuromyelitis optica) ( Techavipoo et al, 2009 ), and two (5.1 %) in patients with other pathologies (traumas, epilepsy) ( Lacerda et al, 2021 , Yang et al, 2011 ) .…”